-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Downgrades InflaRx to Market Perform, Lowers Price Target to $2

Benzinga·12/03/2025 13:37:51
Listen to the news
Leerink Partners analyst Joseph Schwartz downgrades InflaRx (NASDAQ:IFRX) from Outperform to Market Perform and lowers the price target from $5 to $2.